Abstract
Get full access to this article
View all access options for this article.
References
1.BioMarin Pharmaceutical . U.S. Food and Drug Administration Approves BioMarin's ROCTAVIAN™ (valoctocogene roxaparvovec-rvox), the First and Only Gene Therapy for Adults with Severe Hemophilia A . June 29, 2023 . Available from: https://investors.biomarin.com/2023-06-29-U-S-Food-and-Drug-Administration-Approves-BioMarins-ROCTAVIAN-TM-valoctocogene-roxaparvovec-rvox-,-the-First-and-Only-Gene-Therapy-for-Adults-with-Severe-Hemophilia-A [Last accessed:
July 14 , 2023
].
2.
Myshko
D.
FDA Approves $2.9 Million Gene Therapy for Hemophilia A Formulary Watch . June 29, 2023 . Available from: https://www.formularywatch.com/view/fda-approves-2-9-million-gene-therapy-for-hemophilia-a [Last accessed:
June 14 , 2023
].
3.Scribe Therapeutics . Scribe Therapeutics Expands Collaboration with Sanofi to Advance In Vivo Genetic Medicines for Sickle Cell and Other Genomic Diseases . July 17, 2023 . Available from: https://www.scribetx.com/press-release-scribe-therapeutics-expands-collaboration-with-sanofi-to-advance-in-vivo-genetic-medicines-for-sickle-cell-and-other-genomic-diseases/ [Last accessed:
July 17 , 2023
].
4.Astellas Pharma and 4D Molecular Therapeutics . Astellas and 4D Molecular Therapeutics (4DMT) Enter into License Agreement to Use 4DMT's Proprietary Intravitreal R100 Vector for Rare Ophthalmic Targets . July 11, 2023 . Available from: https://www.astellas.com/en/news/28136 [Last accessed:
July 11 , 2023
].
5.Sarepta Therapeutics . Sarepta Therapeutics Announces FDA Approval of ELEVIDYS, the First Gene Therapy to Treat Duchenne Muscular Dystrophy . June 22, 2023 . Available from: https://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-therapeutics-announces-fda-approval-elevidys-first-gene [Last accessed:
June 14 , 2023
].
6.
Blank
C.
First Gene Therapy for Duchenne Priced at $3.2 Million . June 23, 2023 . Formulary Watch. Available from: https://www.formularywatch.com/view/fda-approves-2-9-million-gene-therapy-for-hemophilia-a [Last accessed:
June 14 , 2023
].
7.AVROBIO . AVROBIO to Explore Strategic Altrnatives . July 12, 2023 . Available from: https://investors.avrobio.com/news-releases/news-release-details/avrobio-explore-strategic-alternatives [Last accessed:
July 14 , 2023
].
8.U.S. Securities and Exchange Commission . Form 8-K filed July 12, 2023 . Available from: https://investors.avrobio.com/static-files/9cc9a41d-3e74-4bca-955a-522c94847e65 [Last accessed:
July 14 , 2023
].
9.
Pagliarulo
N.
Avrobio halts gene therapy research and considers a sale BioPharma Dive . July 12, 2023 . Available from: https://www.biopharmadive.com/news/avrobio-strategic-alternatives-sale-gene-therapy-research/686643/ [Last accessed:
July 14 , 2023
].
10.
Philippidis
A.
AGT Spins Out Addimmune, Focusing on Functional HIV Cure. Genetic Engineering and Biotechnology News . July 7, 2023 . Available from: https://www.genengnews.com/gen-edge/agt-spins-out-addimmune-focusing-on-functional-hiv-cure/ [Last accessed:
July 11 , 2023
].
11.
Muvarak
N
,
Li
H
,
Lahusen
T
, et al. Safety and durability of AGT103-T autologous T cell therapy for HIV infection in a Phase 1 trial. Frontiers in Medicine . November 14, 2022 . Available from: https://www.frontiersin.org/articles/10.3389/fmed.2022.1044713/full [Last accessed:
July 11 , 2023
].